Results 51 to 60 of about 25,074 (200)

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

PLoS ONE, 2020
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak, Akil Merchant, Donna M Williams, Ophelia Rogers, Wanke Zhao, Amy Duffield, Linda S Resar, Alison R Moliterno, Zhizhuang J Zhao   +8 more
doaj   +1 more source

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

British Journal of Haematology, EarlyView.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi, Nandakumar Natarajan, Kathryn E. Dickerson, Richard A. Voit   +3 more
wiley   +1 more source

Jugular vein thrombosis: a rare presentation of atypical chronic myeloproliferative disorder in a young woman

Haematologica, 1999
Venous thromboembolism is common in subjects with chronic myeloproliferative disorders and is a recognized presenting feature of occult myeloproliferation.
G Famularo, C Papetti, F Conti, N Petti, F Blandino, C Ruscio, G Mascioli, G Barosi   +7 more
doaj  

Comorbid conditions after allogeneic haematopoietic stem cell transplantation in young adults in Germany—A prospective, multicentre trial

British Journal of Haematology, EarlyView.
Summary Young adults (YA) are particularly affected by comorbid conditions following allogeneic haematopoietic stem cell transplantation (alloHSCT), as they have to live with them for many years. This is the first multicentre prospective study investigating sequelae after alloHSCT in YA in Germany. In total, 107 patients who survived relapse‐free until
Pauline Rocke, Lena Tandetzky, Daniel Wolff, Katharina Egger‐Heidrich, Daniela Heidenreich, Kerstin Schaefer‐Eckart, Eva Wagner‐Drouet, Jochen J. Frietsch, Andreas Hochhaus, Inken Hilgendorf   +9 more
wiley   +1 more source

Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms

Cancer Management and Research, 2010
Joseph Tripodi1, Ronald Hoffman1, Vesna Najfeld2, Rona Weinberg31The Myeloproliferative Disorders Program, Tisch Cancer Institute, Department of Medicine and 2Department of Medicine and Pathology, Mount Sinai School of Medicine, 3The Myeloproliferative ...
Joseph Tripodi, Ronald Hoffman, Vesna Najfeld, et al   +3 more
doaj  

Brain MRI-findings in Ph - negative myeloproliferative disorders

Терапевтический архив, 2019
Myeloproliferative disorders (MPD) are accompanied by a high proportion of thrombotic complications, which may lead to cerebrovascular disease (CVD). Aim.
M M Tanashyan, A L Melikyan, P I Kuznetsova, A A Raskurazhev, A A Shabalina, R N Konovalov   +5 more
doaj   +1 more source

Second primary cancers in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia—cumulative burden without generalized excess cancer risk

British Journal of Haematology, EarlyView.
Summary Second primary cancers (SPCs) are a survivorship concern in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM), but estimates may be influenced by competing mortality and surveillance. We assessed cumulative incidence, relative risk and predictors of SPCs. We studied 521 patients diagnosed with LPL/WM in Region Zealand, Denmark,
Lars Munksgaard, Lars Moeller Pedersen, Lise Mette Rahbek Gjerdrum   +2 more
wiley   +1 more source

Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia

Journal of Blood Medicine, 2013
Violaine Havelange,1,2 Jean-Baptiste Demoulin1 1de Duve Institute, Université catholique de Louvain, Brussels, Belgium; 2Department of Hematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium ...
Havelange V, Demoulin JB
doaj  

Use of selective serotonin reuptake inhibitors and risk of myeloid malignancy: A nationwide Danish case–control study

British Journal of Haematology, EarlyView.
Summary Preclinical and clinical studies suggest that selective serotonin reuptake inhibitors (SSRIs) can stimulate haematopoiesis by promoting proliferation and mobilization of haematopoietic stem and progenitor cells, but whether SSRI use influences myeloid malignancy risk remains unclear.
Katrine Mose, Anton Pottegård, Mette Reilev, Christen Lykkegaard Andersen, Blánaid Hicks, Mathilde Egelund Christensen   +5 more
wiley   +1 more source